Aromatherapy Inhaler Use for HSCT Distress

Not Recruiting

Trial ID: NCT05302583


The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Official Title

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Stanford Investigator(s)

Andrew Rezvani, M.D.
Andrew Rezvani, M.D.

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)


Inclusion Criteria:

   - Autologous and Allogeneic patients admitted to E1 for planned HSCT

   - Patients with hematologic malignancies requiring HSCT

   - No allergies to lavender or peppermint essential oils

   - Must have received chemotherapy during preparative regimen (single or multi-agent

   - Adult patient over 18 years of age

   - Able to speak, read, and comprehend English

   - Willing and capable of providing informed consent

Exclusion Criteria:

   - Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion

   - Patients receiving a transplant for a germ cell tumor diagnosis

   - Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical

   - Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4

   - History of scleroderma

   - History of atrial fibrillation

   - Known history of G6PD deficiency

   - Allergic to lavender or peppermint essential oils

   - Pediatric patient 18 years of age or less

   - Unable to speak, read, and comprehend English

   - Unwilling or incapable of providing informed consent


other: Aromatherapy Inhaler

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305